PharmaSens and SiBionics say they are teaming up to potentially bring a new insulin patch pump system to the diabetes community.
Our sister site, Drug Delivery Business News, reports today that the companies inked a strategic partnership to jointly develop an all-in-one insulin patch pump.
Switzerland-based PharmaSens develops the Niia Essential insulin patch pump system. The basal-bolus patch pump combines the ease of an insulin pen with the advantages of a sophisticated pump. The company submitted the pump to the FDA at the end of 2023 but has not yet announced any approval in the U.S.
China-based SiBionics, meanwhile, develops continuous glucose monitor (CGM) technology, including the GS3 CGM. The company unveiled its CE-marked GS3 earlier this year. It touts the ultra-compact device as the world’s thinnest CGM at the size of a small coin.
Get the full story at our sister site, Drug Delivery Business News.
